Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

Oklahoma’s bioscience prowess busy making a difference worldwide

    Home News Oklahoma’s bioscience prowess busy making a difference worldwide
    NextPrevious

    Oklahoma’s bioscience prowess busy making a difference worldwide

    By sarah | News | 0 comment | 8 June, 2019 | 0

    By Kevan Goff-Parker
    Copyright © 2019 The Oklahoman

    Greater Oklahoma City Chamber Manager of Innovation and Entrepreneurship Evan Fay said he believes some people may be caught off-guard by Oklahoma’s growing bioscience prowess.

    He made his remarks during the final hours Thursday of the Bio International Conference in Philadelphia as the state’s more than 40 OKBio delegates, which included researchers, foundation and university representatives and bioscience and investment companies, continued to meet in face-to-face meetings with representatives from around the world.

    “We’re creating clusters around companies like bioscience, aerospace and defense, energy, and we have a really robust economy,” Fay said. “There’s a lot more activity, whether it’s venture capital investments, accelerator and incubator programs or things that make it easier for entrepreneurs to grow. … It catches a lot of people who aren’t familiar with Oklahoma off-guard that there’s so much activity happening here.”

    The chamber and OKBio delegates are working together to change any misconceptions by those unfamiliar with Oklahoma’s growing economic diversity and progress. He said bioscience is another growing economic segment that demonstrates the state employs much more than just blue-collar workers or is focused strictly on gas and oil production.

    He said the $665 million acquisition of Oklahoma City-based Selexys Pharmaceuticals Corp., by Novartis AG in 2016, is a good example of how a privately held biopharmaceutical company can demand global attention for its research and design capabilities.

    “Oklahomans tend to roll up their sleeves, and they want to help each other. And not by operating in a silo,” Fay said. “It’s a good sharing economy here, and a lot of the work done is behind the scenes in partnership with others, realizing that you can’t do it alone.

    “So we really like to take on that mindset as economic developers in looping together all the right partners, whether that’s i2E, the Oklahoma Center for the Advancement of Science and Technology (OCAST) or the universities.

    “Everyone has a role in lifting up the bioscience community, whether it is on the education side, workforce-development side or mentorship.”

    Mohan Purushothaman, Ph.D., president and CEO of Progentec Diagnostics Inc., has been working in the pharmaceutical business for many years and said he appreciates his company’s partnerships with Oklahoma-based researchers, bioscience professionals and foundations.

    “The company is focused on Lupus. … We license the technology from the Oklahoma Medical Research Foundation, and we’ve been working with OMRF very closely to create something that can really be taken out to the market and provide value to a lot of patients,” Purushothaman said. “We’ve made some tremendous progress and believe we have a very unique (diagnostic testing) solution that can bring some significant value.

    “It’s been great so far and we look forward to some exciting solutions to come out of our company.”

    Lonnie Barish is the vice president of Business Development and Marketing for Cytovance Biologics, an Oklahoma-based contract biopharmacological manufacturing company that was originally founded to treat Pompe disease, a rare neuromuscular disorder.

    “The company has been intimately involved since its early days in drug research and drug development,” Barish said. “We’ve grown quite substantially within the last couple of years supporting all sorts of research on the biologics side. This trade show has turned out to be quite successful for us. … It is still so much better to do business face-to-face and to meet the people you are working with and further those relationships as well.”

    He said Cytovance Biologics is growing at about a “40% clip year after year” and is expanding its employee base, while looking into possibly expanding into gene therapy treatment areas with potential new services by this fall.

    BIO International Show, Evan Fay, Kevan Goff-Parker, Lonnie Barish, Mohan Purushothaman, OKBio

    Related Post

    • Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

      By sarah | Comments are Closed

      Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY, Okla. – May 17, 2022 – Medical device company LinearRead more

    • Student teams from OSU, TU and East Central claim Love’s Cup top awards

      By sarah | Comments are Closed

      May 3, 2022 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org Teams led by student innovators from Oklahoma State University, the University of Tulsa and East Central University claimed first placeRead more

    • A final column and a thank you for reading

      By sarah | Comments are Closed

      Thank you for reading this column for nearly a decade By Scott Meacham This is my final column for The Oklahoman. As CEO of i2E, I have had the wonderful opportunity since January 2013 to write thisRead more

    • A significant impact on new ventures? That’s i2E’s e3 program

      By sarah | Comments are Closed

      Accelerators like i2E’s e3 can have a significant impact on new ventures By Scott Meacham When the team from Zen Health Technologies formally introduces their company, they describe a business that uses immersive technologies for personalRead more

    • Autigen Announces Collaboration with Boehringer Ingelheim

      By sarah | 0 comment

      Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of theRead more

    Leave a Comment

    You must be logged in to post a comment.

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Media
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    100 S. Cincinnati Ave – 5th Floor, Suite 514
    Tulsa, OK 74103
    PHONE 918/582-5592
    Copyright 2022 i2E, Inc. | All Rights Reserved
    • About
    • Entrepreneurship
      • Venture Advisory Services
      • Love’s Entrepreneur’s Cup
      • ACT Tulsa
    • e3
    • Concept Fund
    • Portfolio
    • iMCI
    • ACT Tulsa
    • Contact
    i2E